Shares of Omeros Corporation (OMER) reached a 52-week high of $9.70 in early trading today, reflecting investor optimism surrounding the company's ongoing developments.
Omeros is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics for immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.